KEYTRUDA®

KEYTRUDA® 25 mg/ml is a humanised monoclonal antibody designed to block the PD-1 receptor, enhancing the immune system’s ability to detect and attack cancer cells. It is widely used in immunotherapy treatments for various types of cancer, including melanoma, lung cancer, and head and neck cancers.

Key features

• PD-1 receptor inhibitor: Blocks the programmed death-1 (PD-1) receptor, restoring T-cell immune response against tumour cells.
• Humanised antibody: Engineered to minimise immune reactions and improve treatment compatibility.
• Versatile cancer treatment: Approved for multiple cancers, offering broad therapeutic applications.

Ingredients

• Pembrolizumab (25 mg/ml)

Package content

• Single-use vial containing 4 ml solution (100 mg pembrolizumab).